STAT+: Gilead, Arcus anti-TIGIT drug reduces risk of lung cancer progression in mid-stage study
The Phase 2 study results from Gilead and Arcus could augur a comeback of sorts for the entire class of TIGIT-targeted antibody treatments.
News
This clinical trial wanted to end breast cancer disparities. But first it needed to enroll Black women
Ensuring that trial participants come from diverse backgrounds will mean that the next generation of screening — personalized screening — might have a shot at helping people regardless of their… […]
News
STAT+: Biotech startups are hungry for dollars. Here’s what one pharma executive was looking for at JPM
The balance of power between biotech startups and big pharma has shifted — but Bayer executive Marianne De Backer is still looking for deals. […]
News
Prosecutors: Convicted CEO Elizabeth Holmes is a flight risk
Disgraced Theranos CEO Elizabeth Holmes booked a 2022 flight to Mexico without a scheduled return trip, prompting prosecutors to warn she poses a flight risk while appealing her conviction for… […]
